
Etanercept
CAS No. 185243-69-0
Etanercept( —— )
Catalog No. M34947 CAS No. 185243-69-0
Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 499 | Get Quote |
![]() ![]() |
5MG | 630 | Get Quote |
![]() ![]() |
10MG | 945 | Get Quote |
![]() ![]() |
25MG | 1352 | Get Quote |
![]() ![]() |
50MG | 1831 | Get Quote |
![]() ![]() |
100MG | 2412 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEtanercept
-
NoteResearch use only, not for human use.
-
Brief DescriptionEtanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.
-
DescriptionEtanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
-
In Vitro——
-
In VivoEtanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score.Animal Model:Six-week-old male Lewis rats (adjuvant-induced arthritis (AIA) model) Dosage:10 mg/kg Administration:S.c.; every 3 days for 3 weeks Result:Significantly decreased the mean arthritis scores; Significant decreased in radiological score at the end of the treatment period.
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number185243-69-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111.?
molnova catalog



related products
-
(Rac)-Benpyrine
(Rac)-Benpyrine is a potent and orally active inhibitor of TNF-α.
-
XYLOBIOSE
XYLOBIOSE ia a natural productand exhibited therapeutic potential for treating obesity which involved suppression of fat deposition and obesity-related metabolic disorders.
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.